Singapore markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
67.40+0.70 (+1.05%)
At close: 04:00PM EDT
67.68 +0.28 (+0.41%)
After hours: 07:33PM EDT

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees83,100

Key executives

NameTitlePayExercisedYear born
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director5.99MN/A1959
Dr. Aradhana Sarin M.D.CFO & Exec. Director4.43MN/A1975
Mr. Marc DunoyerCEO of Alexion & Chief Strategy Officer2.1MN/A1952
Ms. Pam P. ChengEVP of Operations & Information Technology and Member of External Sustainability Advisory BoardN/AN/A1971
Mr. Chris SheldonHead of Investor RelationsN/AN/AN/A
Mr. Jeffrey PottEVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory BoardN/AN/AN/A
Ms. Katarina AgeborgEVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory BoardN/AN/AN/A
Gonzalo VinaHead of Global Media RelationsN/AN/AN/A
Dr. Menelas Pangalos Ph.D.EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory BoardN/AN/A1967
Dr. Ruud Dobber Ph.D.Exec. Vice-Pres of BioPharmaceuticals Bus. UnitN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 May 2022 is 5. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.